4D’s Fabry gene therapy on ice after FDA-mandated pause Business, FDA, FDA/Regulatory, R&D, Therapeutics The FDA put 4D Molecular Therapeutics’ gene therapy program, 4D-310, on clinical hold, the company announced February 2. Read more February 6, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/08/FDA-Slams-Sesen-Bio-with-CRL-for-Bladder-Cancer-Drug-BioSpace-8-17-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-02-06 10:00:062023-02-06 10:49:204D’s Fabry gene therapy on ice after FDA-mandated pause
